IOL Chemicals and Pharmaceuticals share news, announcements and annual reports
NSE: IOLCPBSE: 524164Pharmaceuticals & BiotechnologySmall Cap
IOL Chemicals and Pharmaceuticals Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1991 on BSE, Nov 2010 on NSE
Last close ₹177.65down ₹7.28 (3.94%)BSE ₹177.75
Share price at the NSE close on 30 Oct 2026. Previous close ₹184.93.
30 Oct: open ₹186.40, high ₹186.40, low ₹176.02
52-week range of traded prices to 30 Oct 2026
₹67.19Low, 16 Mar 2026₹224.00High, 7 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹5,215 Cr1,024th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.66
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.71
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.56%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 11.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 18,08,91234.0% delivered
IOL Chemicals and Pharmaceuticals share news and announcements
709 announcements, routine notices left out, newest first. Page 2 of 15.
Jan 2026
Dec 2025
5 Dec
Nov 2025
11 Nov · Results
10 Nov · Analysts
Oct 2025
27 Oct · General Updates
24 Oct
Sep 2025
24 Sep
9 Sep · Analysts
8 Sep · Legal
Exchange has sought clarification from IOL Chemicals and Pharmaceuticals Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013 or as per Indian Accounting Standard The response of the Company is awaited.
Aug 2025
22 Aug · Meeting
12 Aug · Analysts
7 Aug · Board meeting
7 Aug · Results
4 Aug · Analysts
Jul 2025
31 Jul · Meeting
28 Jul · Board meeting
22 Jul · Analysts
1 Jul · Rating
Jun 2025
13 Jun · General Updates
11 Jun · General Updates
May 2025
17 May · Management
16 May · Results
14 May · Analysts
6 May · Board meeting
Apr 2025
28 Apr
28 Apr
3 Apr · Analysts
Mar 2025
24 Mar
20 Mar · Analysts
20 Mar
5 Mar · General Updates
Feb 2025
12 Feb · Corporate action